Pharma sector in India: from APIs to formulations

India as the pharmacy of the world

India supplied approximately 20% of global generic drug exports by volume as of the early 2020s and was the primary source of affordable medicines for dozens of low- and middle-income countries. This dominance was not accidental — it was built over three decades through a combination of:

• Large domestic demand that created scale in pharmaceutical manufacturing and a broad base of trained scientists and engineers
• A product patent regime (pre-2005) that allowed Indian companies to manufacture copies of patented drugs for the domestic market, building process chemistry expertise
• Early and sustained investment in obtaining US FDA manufacturing approvals — making India the country with the most FDA-approved pharmaceutical manufacturing sites outside the US itself
• Cost advantages in chemistry synthesis, fermentation, and formulation that were comparable to the IT sector's labour arbitrage in services

The combination of science capability and cost advantage created what is sometimes called the "pharmacy of the world" — a phrase referring to India's role as the low-cost, high-quality global supplier of medicines that would otherwise be unaffordable for billions of people.

The pharmaceutical value chain

Pharmaceutical production follows a sequential value chain:

Step 1: Active Pharmaceutical Ingredient (API) manufacturing

The API is the biologically active molecule in a drug — the compound that actually produces the therapeutic effect. Paracetamol, atorvastatin, metformin, and amoxicillin are examples of APIs. API manufacturing is a chemical process: starting with basic chemical feedstocks (often petrochemical or fermentation-derived), chemists perform a multi-step synthesis to arrive at the pure API molecule.

API manufacturing is capital-intensive, requires specialised chemical engineering expertise, and is heavily regulated (both by the Indian regulatory body CDSCO and by export-destination regulators like the US FDA, EMA in Europe, and WHO for generic aid markets). The primary costs are raw material feedstocks, power, water, and highly skilled chemical engineers.

India has historically depended on China for a significant proportion of key starting materials (KSMs) — the upstream chemical precursors for API synthesis. This dependence became a strategic concern after the COVID-19 pandemic exposed supply chain fragility.

Step 2: Formulation manufacturing

A formulation is the final drug product that a patient takes — a tablet, capsule, injection, ointment, inhaler, or syrup that contains the API plus excipients (inactive ingredients like binders, fillers, coatings, and preservatives that give the drug its physical form and control how the API is released in the body).

Formulation manufacturing requires different facilities from API production. The key capabilities are dosage form development (getting the tablet to dissolve at the right rate, controlling sustained-release kinetics, ensuring stability), quality control testing of each batch, and packaging. Complex formulations — inhalers, liposomal injectables, transdermal patches, modified-release oral drugs — command higher prices and are harder for competitors to copy, making them strategically attractive.

Step 3: Distribution

In India, the formulated drug moves through a multi-tier distribution chain: from manufacturer to national/regional distributor to stockist (city-level wholesaler) to retailer (chemist/pharmacy) to patient. For prescription drugs, a doctor's prescription drives the dispensing. Domestic pharma companies with large sales forces and deep distribution reach — covering small-town and rural pharmacies — have historically commanded brand premiums even on molecules that are technically generic, because a chemist in a small town will dispense a known brand rather than an unknown cheaper alternative.

Domestic vs export: the two revenue streams

Indian pharma companies typically have two distinct revenue segments:

Domestic formulations: sales of branded generics in India. The Indian pharmaceutical market was valued at approximately ₹1.8–2 lakh crore in the early 2020s and was growing at 8–12% per annum, driven by rising chronic disease prevalence (diabetes, hypertension, cardiovascular), improving healthcare access in smaller cities and rural areas, and an ageing population. Margins in domestic branded generics are driven by brand strength, sales force productivity, and doctor relationships.

Export formulations (primarily US): sales of generic drugs into regulated markets, predominantly the United States. The US generic drug market was historically the largest and most profitable generic market globally. However, the US market has become structurally more competitive: as more Indian and other generic companies enter each molecule, pricing erodes over time. A generic drug that launched at 40% of branded price might erode to 5–10% of branded price within 3–5 years as additional generics enter. This pricing erosion is a persistent headwind for US business that companies must offset through new ANDA launches.

The USFDA regulatory pathway

Accessing the US market — the highest-value generics market — requires navigating the US FDA's regulatory framework.

ANDA filings

An ANDA (Abbreviated New Drug Application)is the formal submission to the US FDA for approval to market a generic drug. The application includes the bioequivalence data demonstrating that the generic matches the reference listed drug (the original branded version), the manufacturing process documentation, and certification that all relevant patents have expired or are being challenged. The FDA reviews the ANDA for bioequivalence, chemistry, manufacturing, and controls quality. Approval times historically ranged from 18 months to 3+ years depending on the complexity of the molecule and the FDA's review backlog.

Larger Indian pharma companies — Sun Pharma, Dr Reddy's, Cipla, Aurobindo, Lupin — maintained ANDA pipelines of hundreds of pending approvals. The size and quality of this pipeline is a leading indicator of future US revenue potential.

Facility inspections and import alerts

Even after an ANDA is approved, the manufacturing facility producing the drug must maintain compliance with FDA Current Good Manufacturing Practice (CGMP) standards. FDA inspectors visit Indian manufacturing plants — both for pre-approval inspections (before a new drug can be manufactured for the US) and for routine surveillance inspections.

When inspectors identify significant deficiencies, they issue a Form 483 (Inspectional Observations). If the company's response to a 483 is inadequate, the FDA can escalate to a Warning Letter — a public notice that the facility has serious CGMP issues that must be remediated. The most severe action is an import alert — an order prohibiting the import of any product from that facility into the US.

Import alerts were a significant source of revenue disruption for Indian pharma companies historically. Ranbaxy's Mohali and Toansa plants received import alerts in 2013–2014. Wockhardt received multiple facility bans. Sun Pharma's Halol plant in Gujarat received an import alert in 2014 and went through a multi-year remediation that significantly disrupted its US business before the alert was lifted. These historical episodes underscored the regulatory execution risk in the US-facing business model.

NLEM and domestic price controls

In India, the government regulates the price of drugs on the National List of Essential Medicines (NLEM) through the Drug Prices Control Order (DPCO) administered by the National Pharmaceutical Pricing Authority (NPPA). Drugs on the NLEM have a ceiling price set by the NPPA based on a market-weighted average of existing prices; companies can sell below the ceiling but not above it. Annual price increases are linked to the Wholesale Price Index (WPI) and are capped.

The NLEM was significantly expanded in 2022, bringing more drugs under price control. For pharma companies with heavy domestic branded formulations businesses, the NLEM expansion created pricing pressure on a significant portion of their domestic revenue. Companies with larger proportions of patented, branded, or specialty drugs not covered by NLEM had less exposure to these controls.

The tension between the government's objective of affordable medicine access and the industry's need for returns on R&D and manufacturing investment is a recurring theme in Indian pharma sector analysis. Companies have historically responded by innovating toward non-NLEM segments, launching new molecules, and growing exports — where pricing is not controlled.

Key metrics for pharma analysis

• R&D as % of revenue:pharmaceutical companies must invest in R&D to sustain their ANDA pipeline, develop novel drug delivery systems, and (for more innovator-oriented companies) research new molecules. Indian pharma companies historically spent 5–10% of revenue on R&D — lower than global innovators (which spend 15–20%) but higher than pure generic manufacturers. Rising R&D spend, if well-targeted, is a positive indicator; it can compress near-term profitability but builds the pipeline for future growth.
• ANDA pipeline size and approvals rate:the number of ANDAs pending approval and the historical approval rate is a leading indicator of US revenue potential. Analysts also distinguish between "Para IV" filings (challenging unexpired patents, with potential 180-day exclusivity upside) and standard paragraph III or IV certifications.
• US revenue share: for export-oriented companies, what percentage of total revenue comes from the US determines sensitivity to FDA regulatory actions and US pricing dynamics. A company with 50% of revenue in the US is far more exposed to an import alert than one with 15%.
• EBITDA margin: pharma margins vary significantly by business mix. Pure API manufacturers historically operated on thinner margins (12–18%) than formulation companies. US specialty/complex generics can generate very high margins (25–35%) in exclusivity periods. Domestic branded generics had historically stable margins (20–25%) but with NLEM cap risk.
• Branded vs generic mix (domestic):in India, branded generics — generic molecules sold under a proprietary brand name by a pharma company — historically commanded price premiums over unbranded generics. A company with strong domestic brands (Sun Pharma, Cipla, Dr Reddy's) could sustain higher domestic realisations and margins than companies with only commodity generic products.

Major Indian pharma companies

Sun Pharmaceutical Industrieswas India's largest pharma company by revenue and market capitalisation for most of the 2010s and 2020s. It combined a dominant domestic branded generics franchise with significant US speciality generics and dermatology focus. Its acquisitions of Ranbaxy (2014) and later US dermatology companies built a specialty portfolio that commanded higher US margins than commodity generics.

Dr Reddy's Laboratories was a pioneer in ANDA filings — it was among the first Indian companies to challenge US patents under the Paragraph IV pathway, establishing the template that others followed. It had a significant API business alongside its formulation operations and was historically a leader in complex generics.

Ciplahad a distinctive history — its founder Yusuf Hamied made a global impact in the early 2000s by offering HIV antiretroviral combination drugs to African countries at dramatically lower prices than branded versions, a decision that shaped global access to medicines. Cipla's respiratory franchise (inhalers) was among the most complex technical capabilities in Indian pharma.

Divi's Laboratorieswas the most prominent CDMO-focused company in Indian pharma — it manufactured APIs and intermediates for major global innovator companies under long-term supply agreements. Its business model was fundamentally different from the generics-plus-brands model of Sun/Dr Reddy's/Cipla.

Lupin and Aurobindo Pharma were large generics manufacturers with significant US ANDA portfolios, strong domestic businesses, and growing specialty aspirations.

CDMO/CRAMS: contract manufacturing for global innovators

The CDMO (Contract Development and Manufacturing Organisation) model represents a different strategy from the generics route. Instead of developing its own products and seeking regulatory approvals to sell under its own brand, a CDMO manufactures products on behalf of global innovator companies — providing chemistry, process development, and manufacturing capacity as a service.

The structural appeal of CDMO for Indian companies is significant:

• No requirement to bear the R&D risk of molecule development or the commercial risk of ANDA-based generics pricing
• Long-term supply agreements with high-quality global customers provide revenue visibility
• India's depth of chemistry talent and FDA-approved manufacturing infrastructure makes it a natural destination for innovators seeking to reduce manufacturing costs
• As innovator drugs approach patent expiry (the "patent cliff" — see below), CDMO relationships can transition into authorised generic supply agreements

Divi's Laboratories, Syngene International (Biocon's CRAMS subsidiary), Laurus Labs, and Piramal Pharma were among the companies with significant CDMO revenue in the Indian pharma space.

The PLI scheme: reducing API dependence on China

The COVID-19 pandemic exposed a critical vulnerability in India's pharmaceutical value chain: dependence on China for Key Starting Materials (KSMs) — the upstream chemical feedstocks from which APIs are synthesised. Several KSMs had effectively migrated entirely to Chinese production over the previous two decades as Chinese manufacturers offered lower prices that domestic Indian producers could not match.

In response, the Indian government launched a Production Linked Incentive (PLI) scheme for APIsin March 2020, offering financial incentives tied to incremental sales to manufacturers who set up capacity for 53 critical APIs in India. The scheme aimed to reduce India's import dependence on China for pharmaceutical raw materials. Multiple Indian API manufacturers applied for PLI benefits for fermentation-based APIs, penicillin derivatives, and other critical molecules where Chinese supply had historically dominated.

The effectiveness of the PLI in building sustainable domestic API capacity — given that Chinese production costs remained structurally lower for many molecules — was still being assessed over the subsequent years, with progress varying significantly by molecule and manufacturer.

Patent cliff opportunities

A patent cliffoccurs when a blockbuster drug loses patent protection and generic manufacturers can enter the market. The originator drug's sales typically collapse by 70–90% within 12–24 months of generic entry as cheaper alternatives flood the market. For generic manufacturers, patent cliffs are revenue opportunities — particularly for "first filers" who qualify for 180 days of exclusive generic marketing in the US.

Historically, major patent cliffs in drugs like atorvastatin (Lipitor), clopidogrel (Plavix), and various oncology biologics have created significant revenue windfalls for Indian generics companies that were first to file ANDAs. Because these exclusivity windows are time-limited and non-recurring, analysts must treat patent cliff revenues as one-time or transitional rather than recurring earnings. The key analytical question is what the normalised revenue base looks like after the exclusivity window closes — when the drug becomes a commoditised generic.

Nifty 500 companies in this sector

The Nifty 500 universe includes a significant number of Indian pharmaceutical companies across the value chain — from pure API manufacturers to large-cap branded generics conglomerates. To explore their financial profiles and historical metrics, visit the pharma stocks section of our stocks directory.

This primer is educational only and does not constitute investment advice, a recommendation to buy or sell any security, or research under SEBI (Research Analysts) Regulations, 2014. All historical figures and examples are illustrative and reflect past conditions; past performance is not indicative of future results. Equity markets carry risk, including possible loss of principal. Please consult a SEBI-registered investment adviser before making any investment decision.